Form 4: Passage Bio Executive Edgar B. Cale Acquires 203,000 Stock Options

Edgar B. Cale, GC & Corporate Secretary of Passage Bio, Inc., reports the acquisition of 203,000 employee stock options on March 15, 2024.

Summary

• On March 15, 2024, Edgar B. Cale, the GC & Corporate Secretary of Passage Bio, Inc., acquired 203,000 employee stock options.
• The exercise price of these options is $1.50.
• The options vest monthly, starting April 15, 2024, at a rate of 1/48 of the total shares, contingent upon continued service to the Issuer.
• Following this transaction, Cale directly owns 203,000 derivative securities.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The acquisition of stock options could be viewed as mildly positive, reflecting confidence in the company's future, but it's a routine event.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the stock options is contingent upon the Reporting Person's continued service to the Issuer.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in the biotechnology industry, often used to align management's interests with those of shareholders.
• The vesting schedule of 1/48 monthly is a fairly standard vesting schedule.

Stakeholder Impact

• The acquisition of stock options by a company executive can have a minor positive impact on shareholder sentiment, as it aligns management's interests with those of the shareholders.

Key Dates